CytoDyn Inc. (CYDY) Plans to File IND for Clinical Trial of PRO 140 in Colon Carcinoma Patients following Significant Preclinical Results

August 21, 2018 12:44:34
  • PRO 140 has been shown effective in inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model
  • PRO 140 extended the lives of treated mice and reduced tumor growth by more than 50 percent
  • CytoDyn was recently featured favorably in a report by a leading independent small cap media portal

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) recently announced exciting progress ( in the development of PRO 140 (leronlimab), its novel humanized CCR5 monoclonal antibody, which has multiple therapeutic indications including treating HIV, cancer and inflammatory conditions.

In preclinical studies conducted over the past year, PRO 140 was shown effective in…

Read More>>

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office